Daniel Swartz, MD
General Surgery · Fresno, CANPI 1831134899
Payments from drug & device makers
What this record shows
This record is dominated by education: $50,500 of the $83,338 with a category attached, or 60.6%. Intuitive Surgical accounts for 96.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $39,660 and has fallen 98.8% since, to $486 in 2025. Among general surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $460.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$81K
- Teleflex LLC$381
- Inspire Medical Systems, Inc.$376
- TELA Bio, Inc.$330
- Lilly USA, LLC$248
- Johnson & Johnson$229
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$14,00017%
- Travel & lodging$8,60710%
- Food & beverage$10,23112%
- Education$50,50061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 125 | $80,597 |
| Teleflex LLC | 6 | $381 |
| Inspire Medical Systems, Inc. | 2 | $376 |
| TELA Bio, Inc. | 6 | $330 |
| Lilly USA, LLC | 2 | $248 |
| Johnson & Johnson | 8 | $229 |
| Davol Inc. | 1 | $172 |
| Medtronic | 1 | $168 |
| Covidien LP | 1 | $126 |
| Novo Nordisk | 3 | $95 |
| KARL Storz Endoscopy-america | 5 | $91 |
| Atricure, Inc. | 2 | $86 |
| Edwards Lifesciences | 1 | $81 |
| AbbVie | 3 | $70 |
| Endo Pharmaceuticals Inc. | 4 | $70 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| BD | 1 | $40 |
| Vertex | 2 | $31 |
| Ambu Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Braintree Laboratories, Inc. | 1 | $16 |
| Kls-martin L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$83,338 in reported general payments places this provider in the 95th percentile of 167 general surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $50,377 |
| MounjaroTirzepatide | 15 | $16,320 |
| XareltoRivaroxaban | 16 | $8,857 |
| Omeprazole | 65 | $884 |
| Famotidine | 29 | $579 |
| Topiramate | 23 | $291 |
| Pantoprazole Sodium | 31 | $279 |
| Prochlorperazine Maleate | 23 | $146 |
| Oxycodone Hcl | 14 | $37 |
| Gabapentin | 11 | $9 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $95 | $50,37746 claims |
| Lilly USA, LLCMounjaro | $248 | $16,32015 claims |
| Johnson & JohnsonXarelto | $229 | $8,85716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 167 general surgery providers in California.
Other general surgery in Fresno
- Carlos JuarezFresno$3K
- Daniel MarcusMarina del Rey$43K
- Brian PalafoxOrange$40K
- Houshmand NaimLos Angeles$33K
- Carlos CorveraSan Francisco$25K
- Stevan ClarkLos Angeles$16K
- Yeong AhnLos Angeles$12K
- Jane KakkisFountain Valley$12K
- Michael DeveraLoma Linda$11K
- Monica EigelbergerWalnut Creek$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.